Form 4: Leap Therapeutics Director Exercises Warrants, Acquires Shares

Christopher Mirabelli, a director at Leap Therapeutics, exercised warrants to acquire 2,136 shares of common stock at $2.82 per share.

Summary

• Christopher Mirabelli, Chairman of the Board at Leap Therapeutics, exercised warrants to purchase 2,136 shares of common stock.
• The warrants were exercised at a price of $2.82 per share on November 13, 2024.
• The transaction was executed through Nine Capital Partners, LLC, where Mirabelli is a managing member.
• Mirabelli also has indirect beneficial ownership of 414,480 shares held by HealthCare Ventures IX, L.P. and 261,840 shares held by the HCV VIII Trust.
• Mirabelli disclaims beneficial ownership of these shares except to the extent of his proportionate pecuniary interest.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing for an insider transaction, and does not contain any information that would indicate a positive or negative sentiment.

Industry Context

This is a routine filing related to insider transactions and is common for publicly traded companies. It reflects the exercise of previously issued warrants by a company director.

Comparison to Industry Standards

• The exercise of warrants by a director is a common occurrence in publicly traded companies, particularly in the biotech sector where equity-based compensation is prevalent.
• Similar transactions are regularly reported by directors and officers of comparable companies such as Xencor, Inc. and MacroGenics, Inc.

Stakeholder Impact

• The transaction has a minor impact on shareholders as it increases the number of shares outstanding.

Key Dates

Keywords

Leap Therapeutics, LPTX, Christopher Mirabelli, warrant exercise, beneficial ownership, Nine Capital Partners, HealthCare Ventures